Literature DB >> 17973312

Neurochemical markers of brain damage in cerebrospinal fluid during induction treatment of acute lymphoblastic leukemia in children.

Gustaf Osterlundh1, Ingemar Kjellmer, Birgitta Lannering, Lars Rosengren, Ulf A Nilsson, Ildikó Márky.   

Abstract

BACKGROUND: Central nervous system (CNS) irradiation has been replaced by systemic high-dose methotrexate (MTX) and intrathecal MTX in acute lymphoblastic leukemia treatment due to the risk of late effects. However, treatment without CNS irradiation might also cause brain damage. PROCEDURE: Cerebrospinal fluid (CSF) was analyzed in 121 patients in an attempt to detect CNS injury. Seventy-three samples were analyzed for neuron-specific enolase (NSE), 108 for glial fibrillary acidic protein (GFAp), 110 for neurofilament protein light chain (NFp), and 70 for ascorbyl radical (AsR). Samples were taken at day 0, 8, 15, and 29 during induction treatment, including intrathecal MTX. Levels at days 8, 15, and 29 were compared with the levels before treatment.
RESULTS: NSE levels were 9.0 (+/-3.5) microg/L (mean (+/-SD)) at day 0, 15.0 (+/-5.3) at day 8 (P < 0.001), 13.6 (+/-4.7) at day 15 (P < 0.001) and 11.1 (+/-4.3) at day 29 (P < 0.001). GFAp were 177 (+/-98) ng/L at day 0, 206 (+/-101) at day 8 (P < 0.001), 200 (+/-106) at day 15 (n.s.) and 228 (+/-137) at day 29 (P < 0.001). NFp were below the detection limit 125 ng/L at day 0 in all 110 CSF samples analyzed, and increased significantly above the detection limit in 6/77 samples at day 8, in 11/84 at day 15 and in 22/91 at day 29. The AsR content did not change significantly.
CONCLUSIONS: Levels of NSE, GFAp, and NFp increased in CSF, which can be interpreted as early signs of brain damage. AsR levels do not show any convincing signs of oxidative stress. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17973312     DOI: 10.1002/pbc.21378

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.

Authors:  Yin Ting Cheung; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2015-04-07       Impact factor: 8.989

2.  Plasma glial fibrillary acidic protein levels in a child with sickle cell disease and stroke.

Authors:  William J Savage; Allen D Everett; James F Casella
Journal:  Acta Haematol       Date:  2010-11-24       Impact factor: 2.195

3.  F2-isoprostanes: a measure of oxidative stress in children receiving treatment for leukemia.

Authors:  Marilyn J Hockenberry; Olga A Taylor; Patricia M Gundy; Adam K Ross; Alice Pasvogel; David Montgomery; Phillip Ribbeck; Kathy McCarthy; Ida Moore
Journal:  Biol Res Nurs       Date:  2013-08-15       Impact factor: 2.522

4.  Correlation of cerebral Near-infrared spectroscopy (cNIRS) and neurological markers in critically ill children.

Authors:  Anjali Subbaswamy; Angela A Hsu; Steven Weinstein; Michael J Bell
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

5.  The Longitudinal Parallel Process Analysis of Biomarkers of Oxidative Stress, Symptom Clusters, and Cognitive Function in Children With Leukemia.

Authors:  Mary C Hooke; Daniel Hatch; Marilyn J Hockenberry; Susan Whitman; Ida Moore; David Montgomery; Kari Marano; Pauline Mitby; Michael E Scheurer; Olga Taylor; Wei Pan
Journal:  J Pediatr Oncol Nurs       Date:  2020-03-06       Impact factor: 1.636

6.  Treatment of acute lymphoblastic leukemia from traditional chinese medicine.

Authors:  Ya-Li Hsiao; Pei-Chun Chang; Hung-Jin Huang; Chia-Chen Kuo; Calvin Yu-Chian Chen
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-22       Impact factor: 2.629

Review 7.  Chemotherapy and the pediatric brain.

Authors:  Chrysanthy Ikonomidou
Journal:  Mol Cell Pediatr       Date:  2018-11-06

Review 8.  Cerebrospinal Fluid Biomarkers in Childhood Leukemias.

Authors:  Chrysanthy Ikonomidou
Journal:  Cancers (Basel)       Date:  2021-01-24       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.